A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Trial Profile

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Flortaucipir F 18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Sponsors Avid Radiopharmaceuticals
  • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
    • 09 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 16 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top